DexCom, Inc. (NASDAQ:DXCM) Stock Position Decreased by Hantz Financial Services Inc.

Hantz Financial Services Inc. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 95.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 907 shares of the medical device company's stock after selling 21,210 shares during the quarter. Hantz Financial Services Inc.'s holdings in DexCom were worth $61,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Blue Whale Capital LLP lifted its holdings in DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after acquiring an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC raised its stake in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after buying an additional 11,075 shares during the last quarter. Brooktree Capital Management acquired a new position in shares of DexCom during the 3rd quarter worth $683,000. National Pension Service raised its stake in shares of DexCom by 4.1% during the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company's stock worth $63,671,000 after buying an additional 37,363 shares during the last quarter. Finally, Intact Investment Management Inc. purchased a new stake in DexCom during the 3rd quarter worth about $650,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company's stock, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,431 shares of company stock valued at $399,319. Company insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent research reports. Royal Bank of Canada dropped their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Wells Fargo & Company lifted their price target on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, October 25th. JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Oppenheimer lowered their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Stock Performance

NASDAQ DXCM traded up $1.60 during trading hours on Tuesday, hitting $80.91. The company had a trading volume of 3,551,800 shares, compared to its average volume of 3,917,172. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business has a fifty day simple moving average of $71.58 and a 200-day simple moving average of $87.18. The firm has a market cap of $31.60 billion, a P/E ratio of 48.45, a price-to-earnings-growth ratio of 2.43 and a beta of 1.12.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.